Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02LJW
|
|||
| Former ID |
DNCL002283
|
|||
| Drug Name |
Tirbanibulin
|
|||
| Synonyms |
KX2-391; 897016-82-9; KX-01; UNII-4V9848RS5G; N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide; KX-2-391; CHEMBL571546; 4V9848RS5G; KX2391; KX 01; KX-2391; MLS006011272; SCHEMBL153779; KX01; GTPL7957; DTXSID30237862; MolPort-023-293-512; HUNGUWOZPQBXGX-UHFFFAOYSA-N; HMS3656J15; EX-A2434; BCP02845; ZINC43152787; s2700; BDBM50303801; AKOS027276392; KX2-391; KX-01; SB16619; CS-0248; KX2-391 (KX01); BCP9000828; 2-Pyridineacetamide, 5-(4-(2-(4-morpholinyl)ethoxy)phenyl)-n-(phenylmethyl)-; NCGC00346644-05; NCGC00346644-01; KX 2
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Actinic keratosis [ICD-11: EK90.0; ICD-10: L57.0; ICD-9: 702] | Approved | [1] | |
| Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 2 | [2], [3] | ||
| Company |
Kinex Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H29N3O3
|
|||
| Canonical SMILES |
C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4
|
|||
| InChI |
1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)
|
|||
| InChIKey |
HUNGUWOZPQBXGX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 897016-82-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
46498254, 56022368, 103705703, 104158162, 136348848, 136349562, 136367693, 139945858, 144116117, 152258184, 160647020, 162011612, 162038097, 162202694, 164339429, 172650552, 172919161, 174006559, 180413315, 186014844, 189622849, 198936538, 223705273, 224205246, 226518343, 242861494, 246186859, 249565640
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tubulin polymerization (TubP) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7957). | |||
| REF 3 | ClinicalTrials.gov (NCT01074138) A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.